2023
DOI: 10.1093/ecco-jcc/jjac190.0890
|View full text |Cite
|
Sign up to set email alerts
|

P760 Adalimumab biosimilars versus Azathioprine: indirect comparison of efficacy, safety and persistence in treatment

Abstract: Background The advent of low-cost adalimumab (ADA) biosimilars is expected to increase access to biologics. Whether ADA biosimilars influence the use of conventional immunomodulators, especially azathioprine (AZA), which should be the alternative in steroid-dependant IBD, has not been investigated and comparative data on efficacy and safety are scanty. The aim of this study is to compare ADA biosimilars and Azathioprine (AZA) in patients with IBD naive to biologics and/or immunosuppressive ag… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles